After a massive Phase IIb fail, antiviral biotech Virios is scrambling to bring in extra capital — all while the biotech’s shares have now reached their lowest point so far.

In the wake of disclosing its clinical trial failure early Monday, Virios announced later that day that it was going for a public offering. While the company’s first statement didn’t say much, the biotech said that it plans to use the money raised to further advance the biotech’s candidate that failed, IMC-1, through clinical development and set some aside for working capital.

While several companies have been finding success in the TCR-T cell therapy space — with Intellia having its treatment accepted by the FDA last year — another company is using machine learning to get in on the action and find a candidate to bring toward the clinic.

ImmunoScape, a biotech based in Singapore and California, has raised $14 million in a fresh round of financing. The company itself was founded in 2016 as a spinout from the Singapore-based Agency for Science, Technology and Research, setting up its US operations in San Diego in 2020.

California-based biotech Ventyx Biosciences has managed to snap up quite a bit of cash since emerging last year, and its latest move will hope to give the company another nine-figure boost.

On Monday, Ventyx announced that it is looking to raise around $176.6 million, which will extend the biotech’s cash into 2025. A statement said that the funds will be going toward funding the development of the four candidates in the company’s pipeline, funding additional research and other uses.

California-based biotech Allakos, which works on allergies and inflammation-related diseases, is making hay while the sun shines.

Ten days after announcing lukewarm results of its lead drug candidate, the company announced it was seeking $150 million via an underwritten offering of shares of its common stock $ALLK.

The company’s 24-week data from its Phase III trial EoDyssey was investigating its lead drug candidate lirentelimab in patients with confirmed eosinophilic duodenitis — a chronic inflammatory disease characterized by inflammation in the stomach and part of the small intestine.

Third Harmonic Bio pulled it off.

The Atlas-founded biotech, which came out of stealth just earlier this year with former Audentes CEO Natalie Holles at the helm, has priced an IPO that will bring in $185.3 million before taking commissions, discounts and other fees into account.

Given the chilly public market, it is perhaps unusual that Third Harmonic is making the jump to Nasdaq at all. Notably, while it priced in the middle of the proposed range — $17 per share — the company is boasting of an upsized offering. It ended up selling more than 10 million shares rather than the 9 million originally planned.

A biotech with connections to Roche’s Genentech has now landed its newest cash infusion.

Microbiome outfit Novome Biotechnologies said Tuesday that it has now secured $43.5 million in new financing via a Series B round. The funds, according to the company, will be used to advance its lead candidate through an ongoing Phase IIa — and advance other candidates for a potential indication in inflammatory bowel disease.